Back to GOLDMAN SACHS GROUP INC GOLDMAN SACHS GROUP INC

ARQTARQT
7 quarters

Position history for GOLDMAN SACHS GROUP INCGOLDMAN SACHS GROUP INC's holdings in ARCUTIS BIOTHERAPEUTICS INC

GOLDMAN SACHS GROUP INC holds 1.7M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), worth $43.7M as of 2026-Q2. The position was increased (+4.1% shares). ARQT represents 0.0% of GOLDMAN SACHS GROUP INC's portfolio.

Current Value

$43.7M

Current Shares

1.7M

Total Value Change

+$25.5M

Total Shares Change

+362,200

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.7M
+4.1%
$43.7M0.0%$26.22
30
2026-Q1
Increased
1.6M
+1.7%
$37.8M0.0%$23.56
29
2025-Q4
Decreased
1.6M
-12.7%
$45.8M0.0%$29.04
0
2025-Q3
Decreased
1.8M
-4.5%
$34M0.0%$18.85
0
2025-Q2
Increased
1.9M
+71.3%
$26.5M0.0%$14.02
43
2025-Q1
Decreased
1.1M
-15.5%
$17.3M0.0%$15.64
0
2024-Q4
New
1.3M
-
$18.2M0.0%$13.93
39

Other major holders of ARQT: BlackRock, Inc., JENNISON ASSOCIATES LLC, VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used